What is it about?
Our findings demonstrate that in atrial fbrillation patients treated with vitamin K antagonists, impaired fibrinolysis predisposes to thromboembolism, but not to bleeding.
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
Our study suggests that clot lysis time (CLT) may provide additional prognostic information for anticoagulated patients with AF
Perspectives
The present study supports the concept of a biomarker-based approach in thromboembolic risk assessment in patients with AF. We demonstrated that clot lysis time (CLT) may refine clinical risk stratification of cerebrovascular events because the highest risk ofstroke or TIA during follow-up was observed in AF patients with high-risk clinical criteria combined with prolonged CLT. It might be speculated that CLT could be incorporated in the risk scales of AF-related thromboembolic events, and its assessment may help to adjust initial risk as reported in pa- tients following acute coronary syndrome
Leszek Drabik
Uniwersytet Jagiellonski w Krakowie
Read the Original
This page is a summary of: Clot Lysis Time Predicts Stroke During Anticoagulant Therapy in Patients with Atrial Fibrillation, Canadian Journal of Cardiology, August 2019, Elsevier,
DOI: 10.1016/j.cjca.2019.08.001.
You can read the full text:
Resources
Contributors
The following have contributed to this page
